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Abstract  27 
Although different colon-targeting methods such as pH and time-dependent as well as 28 
bacterially degradable systems have been developed, due to variations in physiological 29 
conditions of patients, one system alone cannot produce a reliable drug delivery system. 30 
Therefore, in this study, an attempt was made to formulate 5-ASA pellets based on a 31 
combination of pH and time-dependent systems. A 32 full-factorial design was used to 32 
evaluate the effect of sodium alginate (SA) concentration and the polymer ratio (Eudragit® 33 
RS: Eudragit® S100) on morphology, mechanical features and release behaviour of 5-ASA 34 
pellet formulations. Fourier transform infrared spectroscopy, and differential scanning 35 
calorimetry analysis ruled out any interactions between the formulations components. The 36 
optimized formulation released 35, 55 and 89% of the drug within 15 h, at pHs 1.2, 6.8 and 37 
7.4, respectively. In vivo studies demonstrated that the administration of sodium alginate-38 
based matrix pellets containing 5-ASA coated with ES100 was effective in alleviating the 39 
damaged tissues and also decreased the inflammatory score and the rate of weight loss in 40 
colitis rats. The results indicated the remarkable anti-inflammatory efficacy of the designed 41 
colonic delivery system and the proposed formulations can be further developed in the 42 
pharmaceutical industry for patient use.  43 
 44 
Keywords: 5-aminosalicylic acid, Alginate, Eudragit® RS, Eudragit® S100, Pellet, In vivo 45 
  46 
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1. Introduction 47 
5-aminosalicylic acid (5-ASA) is an anti-inflammatory drug, which is commonly used in the 48 
treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's 49 
disease (CD) [1]. But most of orally administered 5-ASA molecules are capable of being 50 
absorbed or degraded in the stomach and small intestine before they reach the colon [2]. In 51 
recent years, it has become possible to deliver drugs to the colon in a specific manner. Colon-52 
specific delivery systems could prevent the release of the drug in the upper part of the 53 
gastrointestinal tract (GIT), and they use a triggering mechanism that causes sudden drug 54 
release upon reaching the colon [3]. Many studies have been focused on the design of colon-55 
targeted drug delivery system (CDDS), which drug release mechanisms are based on a 56 
physiological characteristic of GIT such as pH, time and bacterial or combinations of them 57 
[4–7]. 58 
pH-dependent systems utilize the pH changes along the GIT to control drug release. 59 
Eudragit® S100 (ES100) is an anionic pH-dependent copolymer based on methacrylic acid 60 
and methyl methacrylate (1:2 ratio). ES100 is insoluble in acids and pure water, whereas 61 
soluble in aqueous solution at pH 7.0 or higher [8]. It is reported that ES100 as a pH-sensitive 62 
matrix former influenced the pellet size and roundness, and also failed to delay the drug 63 
release [9]. However, 5-ASA pellets coated with ES100 were resistant to gastric and upper 64 
intestinal pH while quickly released the drug at pH>6.8 [10]. 65 
Furthermore, natural polymers with acidic or basic groups have been employed as carriers for 66 
colon-specific drug delivery due to their non-toxicity, biocompatibility and easy availability 67 
[11]. Alginate is a natural polymer that has been widely used as drug carriers for oral 68 
administration [12]. Also, the potential therapeutic effect of sodium alginate (SA) in colitis 69 
rats in reducing inflammation was reported [13,14]. The presence of carboxylic groups in 70 
alginate structure makes it very sensitive to the pH changes in the surrounding environment 71 
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of this polymer. Theoretically, alginate shrinks at low pH of the gastric environment and the 72 
drug cannot be released [15]. Therefore, pH-responsiveness of this polymer has been 73 
exploited for the development of oral colon-specific drug delivery devices [16]. Time-74 
dependent systems are designed to achieve colon-specific delivery by utilizing the transit 75 
time for the formulation to pass through the upper GIT. Eudragit® RS (ERS) is an acrylic 76 
polymer that swells and releases the incorporated drug via diffusion and erosion. Its 77 
combination with other polymers in matrix pellets could relatively control drug release in the 78 
upper GIT [17].  79 
Various dosage forms have been developed to provide controlled release and colon-targeted 80 
delivery of 5-ASA. Multi-particulate dosage forms (e.g., pellets, granules, or microparticles) 81 
offer several advantages such as more homogenous drug distribution and better drug 82 
absorption compared to single-unit dosage forms (e.g., tablets or capsules) [18]. Pellets are 83 
spheres with a diameter of 500-1500 µm that have several technological and therapeutical 84 
advantages including enteric protection of the particles or controlling the drug release, and 85 
wide dispersion in the GIT. Among the techniques employed for preparing pellets, extrusion-86 
spheronization has gained particular attention due to the highly uniform particle size 87 
distribution of the resultant pellets [19]. These pellets can be produced as matrix pellets with 88 
the appropriate polymer and are coated in the fluid-bed unit to provide modified release 89 
dosage forms [20].  90 
Although the in vitro release conditions can potentially be crucial for the observed drug 91 
release the in vivo studies of this type of dosage forms also seems necessary [21]. For 92 
instance, in vivo studies showed that the administration of chitosan pellets containing 5-ASA 93 
coated by pH-sensitive Eudragit® FS which controlled the delivery of the drug to the colon 94 
decreased the colon/body weight ratio in colitis rats [22]. In another study, the rat model of 95 
ulcerative colitis showed the optimal therapeutic effect when 5-ASA pellets containing 96 
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Surelease® and Eudragit® S100 as a drug carrier [23]. Similar results observed for coated 97 
pellets of 5-ASA in different studies [24,25]. 98 
The aim of this study was to design pH and time-dependent 5-ASA matrix pellets containing 99 
SA, ERS, and ES100 with a capability to release the dug at the desired site of the action when 100 
is tested on colitis rats.  To this end, a 3-level full factorial design was employed to explore 101 
the process variables involved in the optimization of the pellets formulations. The effect of 102 
the explored factors was also investigated on the pellets characterization, mechanical 103 
parameters as well as the dissolution behaviour of the drug from the optimized pellets.  104 
 105 
2. Materials and methods 106 
2.1. Materials 107 
5-ASA was purchased from Arya pharmaceutical co. (Tehran, Iran), microcrystalline 108 
cellulose (Avicel® PH101) were provided by Darupakhsh (Tehran, Iran), calcium carbonate 109 
and potassium phosphate monobasic were supplied from Merck (Germany), sodium alginate 110 
(number-average molecular weight 12,000–40,000 and viscosity 5.0-40.0 cps) was purchased 111 
from Sigma-Aldrich (USA), Eudragit® RS PO and Eudragit® S100 were provided from 112 
Evonik® (Germany). All excipients used to prepare pellets and coating were of standard 113 
pharmaceutical grade, and all chemical reagents used were of analytical grade. 114 
  115 
2.2.Preparation of pellets 116 
The solid components of each formulation (Table 1) were mixed for 10 min, and then 117 
sufficient amount of water as a granulating liquid (this was not measured) was added slowly 118 
to the mixture to make a wet mass (past-like) with a suitable consistency. The wet mass was 119 
passed through an axial screw extruder (type HC 732, Dorsa, Iran) with a 1 mm screen at 100 120 
rpm. The extrudates were rounded by a spheronizer (type HC 732, Dorsa, Iran) with a cross-121 
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hatched plate at 1000 rpm for 5 min. The obtained pellets were dried and cured at 70 °C in an 122 
oven (Parseh ON-12, Iran) for 7 h [17]. 123 
The pellets were coated in a fluidized-bed coating apparatus (Wurster insert, Werner Glatt, 124 
Germany). ES100 solution (10% w/v) was prepared in isopropyl alcohol:water (9:1) mixture. 125 
Then, 10% (w/w) dibutyl phthalate related to the dry polymer as a plasticizer was added 126 
directly to the polymer dispersions. This was followed by the addition of 5% w/w talc 127 
(related to dry polymer) as a glidant. The inlet air temperature was set at 40 °C, and the outlet 128 
temperature was in the range of 25–35 °C. The atomizing pressure was 2.0 bar, and the spray 129 
rate was 10 g/min. 200 g of 5-ASA pellets were coated in fluidized-bed coating apparatus to 130 
achieve a 10% (w/w) weight gain. The pellets were fluidized for an extra 5 min, and samples 131 
were kept in an oven for 2 h at 40 °C [26].  132 
 133 
2.3.Morphology of pellets 134 
Pellets were sieved with standard sieves mesh size 16 and 35 and shaken for 5 min. The 135 
pellets that remained on the sieve with mesh 35 (size range 500-1180 µm) were considered as 136 
appropriate pellets, and the weight of pellets in this range was reported as the yield of pellets. 137 
Microscopic image analysis was used to determine the shape and size of the pellets. About 20 138 
pellets from each batch were attached on a black matt background, and a top light source was 139 
used to remove the influence of shadow on the image processing. Image analyzer consisted of 140 
a stereomicroscope (Olympus, DP25, Okura, Japan) at magnification (8.5×) and a digital 141 
camera (Sony, Japan). Digitized images were analyzed by the image analyzing software 142 
(ImageJ 1.50f for Windows). The area (A), perimeter () and the longest and shortest 143 
Feret’s diameters (dmax and dmin) of pellets were measured, and two shape factors were 144 
calculated as followed [27]: 145 
Aspect ratio = dmax / dmin (1) 
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Sphericity = 4πA / 		  (2) 
Also, surface characteristics of pellets were examined by scanning electron microscope 146 
(SEM) (LEO1450 vp, Zeiss Company, Germany).  147 
 148 
2.4.Mechanical tests 149 
The crushing strength (CS; force needed to break the pellets) of 20 pellets (500-1180µm size 150 
fraction) was measured using a testing machine equipped with a 1kN load cell (Hounsfield-151 
H50KS, United Kingdom). The speed of the upper mobile plate was set at 1 mm/min [28].  152 
 153 
2.5.Fourier transform infrared spectroscopy 154 
FT-IR spectroscopy was accomplished in KBr discs over a range of 4000–500 cm-1 using IR 155 
spectroscope equipment (vortex 70, Bruker, Germany).  156 
 157 
2.6.Differential scanning calorimetry  158 
Differential scanning calorimetry was performed by DSC (Metler Teldo DSC822, 159 
Switzerland) to evaluate thermal behaviour of the pellets and also to investigate any 160 
interaction between the excipients and the drug used in the formulation of the pellets. The 161 
samples were heated from 50 to 250 °C at a heating rate of 10 °C/min. 162 
 163 
2.7.Determination of drug content in pellets 164 
To determine the drug content in pellets, accurately a certaine amount of pellets (250 mg 165 
which is equivalent to the 50 mg drug) was added to 250 mL of phosphate buffer pH 7.2 in a 166 
volumetric flask. The volumetric flask was shaken in water bath at 37 °C for 10 hr. Dilutions 167 
were made suitably and measured for the drug content by UV spectrophotometry at 330 nm. 168 
Assays were carried out in triplicate and the mean value was reported. 169 
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 170 
2.8.In vitro dissolution studies 171 
Dissolution studies of uncoated and coated pellets were done with a basket method (USP 172 
apparatus I) in the 900 mL medium at 37 °C at a rotation speed of 100 rpm (Pharmatest, 173 
Germany). An accurate amount of pellets equivalent to 50 mg of 5-ASA were weighed and 174 
transferred to the basket of dissolution medium. The dissolution tests were performed for 2 h 175 
in pH 1.2 (HCl 0.1N) and 10 h in the phosphate buffer media (pHs 6.8 and 7.4). The samples 176 
were taken from the vessel by a peristaltic pump (Alitea. Sweden) and passed through a 177 
multi-cell system on the UV spectrophotometer (Shimadzu, Japan) and assayed at 302 nm 178 
(for acidic media) and 330 nm (for buffer media) and returned to the vessel (n=3).  179 
From drug release data, mean dissolution time (MDT) was computed via the following 180 
equations [29]: 181 
 =
∑ 
̅ . ∆
∑∆
 
(3) 

̅ =

 + 

2
 
(4) 
∆ =  − (5) 
Where 
̅ is the midpoint of the time during which the fraction ∆ of the drug released from 182 
the dosage form. A high MDT value means that the drug delivery system has a slow in vitro 183 
drug release. 184 
The continuous dissolution test was performed for the most promising formulation (F11 185 
coated with 10% ES100) based on accepted GIT times; 2 h for pH 1.2 (simulating gastric 186 
fluid), 3 h for pH 6.8 (simulating Duodenum) and 10 h for pH 7.4 (stimulating lower small 187 
intestine and colon), respectively. The 5-ASA cumulative release percentage was calculated 188 
over the sampling times. 189 
 190 
 191 
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 192 
2.9.Experimental design  193 
A 32 full factorial design was used for the optimization procedure. The independent variables 194 
were SA concentration (X1) and ERS/ES100 ratio (X2), each at three different levels as shown 195 
in Table 2. The dependent variables were aspect ratio (Y1), sphericity (Y2), CS (Y3), MDTa in 196 
pH 1.2 (Y4) and MDTb in pH 6.8 (Y5).  197 
The effect of independent variables on the responses was modeled with the help of Design-198 
Expert® software version 11.0.3.0 (Stat-Ease, Inc., USA) using following polynomial 199 
equation: 200 
Y = b0 + b1 X1 + b2 X2 + b11 X12 + b22 X22 + b12 X1 X2  (6) 
Where Y is the measured response, Xi is the level of the ith factor; b0 represents the intercept, 201 
and bi, bij ... represent coefficients computed from the responses of the formulations in the 202 
design. 203 
ANOVA was applied to further reducing the generated polynomial equations on the basis of 204 
significant terms. The 32 full factorial design was validated for selected formulations. The 205 
predicted values for CS, MDTa, and MDTb were determined on the basis of respective 206 
polynomial equations whereas the experimental (observed) values were determined by 207 
evaluating formulations for the selected dependent variables. The predicted and observed 208 
values of the responses were compared for statistical significance using a paired t-test. 209 
 210 
2.10. In vivo studies 211 
Male Wistar rats (280±40 g), aged 8–12 weeks, were housed in 12 h light/dark cycles at 22±3 212 
°C and allowed free access to water and standard laboratory food duration of the studies (the 213 
standard laboratory food is oval pellet, 10 mm × 16 mm × 25 mm length, so that the animals’ 214 
requirements such as energy, protein, calcium, phosphorus, methionine, and lysine could be 215 
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attained. This oval pellet contains ground corn, dehulled soybean meal, fish meal, wheat 216 
middlings, cane molasses, dehydrated alfalfa meal, soybean oil, ground oats, dried beet pulp, 217 
wheat germ, brewers dried yeast, dicalcium phosphate, calcium carbonate, salt, DL-218 
methionine, choline chloride, cholecalciferol, menadione dimethylpyrimidinol bisulfite 219 
(source of vitamin K), pyridoxine hydrochloride, vitamin A acetate, biotin, thiamine 220 
mononitrate, vitamin B12 supplement, dl-alpha tocopheryl acetate (form of vitamin E), 221 
nicotinic acid, calcium pantothenate, riboflavin supplement, manganous oxide, zinc oxide, 222 
ferrous carbonate, copper sulfate, zinc sulfate, calcium iodate, cobalt carbonate). Rats fasted 223 
for 24 h with free access to water before the induction of colitis. The experimental method 224 
involving animals was conducted in accordance with the National Institutes of Health guide 225 
for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). It was 226 
also approved by the Institutional Animal Care and Use Committee, Mashhad University of 227 
Medical Sciences, Mashhad, Iran, with the ethical number IR.MUMS.SP.1395.63. 228 
 229 
2.10.1.  Induction of colitis 230 
Inflammatory lesions were induced in a method described by Millar et al. [30]. Each rat was 231 
anaesthetized by ketamine/Xylazine (1:3, v/v), received 2 mL acetic acid 3% (prepared in 232 
normal saline 0.9%), and through anus using a polyethylene tube (2 mm in diameter) which 233 
inserted 8cm into the colon and the fluid was withdrawn after the 30s. 234 
 235 
2.10.2. Treatment and experimental design  236 
After 5 days of colitis induction, rats were randomly divided into four groups (5 animals in 237 
each group): normal control group (colitis was not induced), negative control group (no drug 238 
was administered after colitis induction), vehicle-treated group (1% Na-CMC), positive 239 
control group (received 5-ASA pellets with vehicle) and ES100 coated 5-ASA pellets 240 
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(received with vehicle) treated group (Figure 1). A dose of 120 mg/kg/day of 5-ASA 241 
calculated from the dose from humans (70kg) [31] was administered by oral gavage once a 242 
day for five consecutive days. Food and water were allowed throughout the treatment. After 243 
five days the rats were sacrificed, and the colon segments were removed. The damage of the 244 
colon sample was evaluated by macroscopic scoring and histological examination. The 245 
weight-loss of each group was tracked every day after colitis induction and also their weight-246 
gain was recorded after the onset of the treatment. Rats that had more than 80% weight loss 247 
(weight less than 195 g) were omitted from the study, also rats with bloody diarrhoea, 248 
prolonged prostration and fever were excluded. 249 
 250 
2.10.3. Assessment of colitis 251 
Macroscopic scoring of the colon (8 cm), extending proximally for 2cm above the anus was 252 
removed. The colonic tissues were preserved in formalin (10% v/v) solution to prevent 253 
autolysis and were split longitudinally. The macroscopic assessment of the colonic damage 254 
was scored according to Table 6 criteria which were reported elsewhere [32]. The 255 
histopathological study was performed on sections of colon tissues. Cross-sections of colon 256 
segments were fixed in 10% buffered formalin solution (pH 7.4). The sections were stained 257 
with haematoxylin and eosin (H&E) followed by microscopic observations [33]. Histological 258 
evaluation of colonic damage was assessed by a light microscope equipped with a digital 259 
camera. 260 
 261 
2.11. Statistical analysis  262 
Data were expressed as means ± SD. For statistical evaluations of histological results, non-263 
parametrical ANOVA (Kruskal-Wallis test) was used, and one-way ANOVA followed by 264 
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Tukey test was applied for comparing body weights. A value of p-value<0.05 was considered 265 
significant. 266 
 267 
 268 
3. Results and discussion 269 
3.1. Characteristics of pellets 270 
The content of 5-ASA in pellet, as estimated by UV spectrophotometry, was 18.7 ± 2 % w/w 271 
which indicated the coherent distribution of the drug by extrusion-spheronization process.  272 
The results of the yield of different formulations of pellets showed that approximately 88% of 273 
the uncoated pellets were within the desired size range of 500–1180µm (Table 3). Also, 274 
image analysis results revealed that the aspect ratio and sphericity of pellets were near to 1 275 
(Table 3) which shows that SA concentration has not affected these parameters and the 276 
extrusion-spheronization process provides almost spherical pellets. Similarly, Charoenthai et 277 
al. produced spherical pellets by including SA in the formulations [34].  278 
SEM data were used to confirm the results of image analysis (aspect ratio and sphericity) as 279 
well as the surface of uncoated and coated pellets (Figure 2). The surface of the uncoated 280 
pellets was smooth, and also, the coated pellets show that the coating layer is uniform and 281 
formed continuously. Duan et al. also obtained spherical and smooth-face in shape after 282 
coating alginate based microparticulates with ES100 [35]. The cross-section of coated pellets 283 
was shown in Figure 2D and it revealed the thickness of the coating layer was about 8-10 µm. 284 
After continuous dissolution test, the uniform coating layer (Figure 2C) changed to a porous 285 
surface (Figure 2F) which facilitated the drug release throughout these pores. This was 286 
probably due to the dissolution of ES100 above pH 7.0. 287 
 288 
3.2. FTIR  289 
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The characteristic peaks of 5-ASA spectra (Figure 3a) corresponded to 2500–3000 cm−1 290 
(stretching vibrations of the hydrogen bonds), 1642 cm−1 (C=O stretch), 1451cm−1 (NH 291 
blend), 1352cm−1 (C–N stretch). In the case of ES100 (Figure 3b) the peak at 1729 cm−1 was 292 
attributed to the esterified carboxyl groups. ERS showed an ester C=O stretching peak around 293 
1738 cm-1 (Figure 3c). The spectrum of alginate (Figure 3d) showed important absorption 294 
bands regarding hydroxyl, ether and carboxylic functional groups. Stretching vibrations of 295 
O–H bonds of alginate appeared in the range of 3000–3500 cm−1. Stretching vibrations of 296 
aliphatic C–H were observed at 2928 cm−1. The observed bands in 1650 and 1450 cm−1 were 297 
attributed to asymmetric and symmetric stretching vibrations of carboxylate salt ion, 298 
respectively. The presence of characteristic peaks of the drug in the FT-IR spectra of the 299 
physical mixture (pellet) indicates the absence of chemical interaction between the drug and 300 
the polymers (Figure 3e). FT-IR has been used in other studies to confirm the presence or 301 
lack of interaction between drug and polymers [36,37]. 302 
 303 
3.3. DSC 304 
The pure 5-ASA (Figure 4a) showed a sharp endothermic peak at 284.5°C that corresponded 305 
to drug melting point due to its crystalline nature [38]. In the case of ES100 and ERS (Figure 306 
4b, 4c), glass transition temperature region and an endothermic peak were observed at 307 
216.2°C and 70.1°C, respectively [8,39]. The DSC trace of alginate (Figure 4d) shows a 308 
broad endothermic peak around 91.0°C and a sharp exothermic peak at 250.8°C. These peaks 309 
may be caused by the loss of water and moisture content and thermal decomposition of the 310 
polysaccharide, respectively. A physical mixture of 5-ASA, ES100, ERS and alginate (pellet) 311 
as a positive control (Figure 4e) showed a broad endothermic peak around 79.2°C which is 312 
probably related to the overlapping of the glass transition peaks of Eudragits and the loss of 313 
water and moisture content. Also, the endothermic peak of 5-ASA was absent in the DSC 314 
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traces which is probably due to a reduction in the crystallinity of the drug. Therefore it could 315 
be concluded that the polymorphic changes ocurred during the extrusion-spheronization 316 
process [8,40]. 317 
 318 
3.4. In vitro dissolution studies 319 
An effective colonic drug delivery system must remain intact in the upper GIT, i.e., the 320 
physiological environment of the stomach and be able to release the majority of its drug 321 
content in the colonic medium [41]. The small intestine is divided into two major parts: upper 322 
parts with nearly pH 6.8 and residence time of 3h, the lower part and terminal ileum with pH 323 
7.4 and residence time of 1h [42]. Regarding this fact, the dissolution tests were carried out 324 
using change over media (pH 1.2, 6.8 and 7.4). Primary dissolution results of the uncoated 325 
pellets in pH 1.2 and 6.8 indicated that more than 90% drug released from all formulations in 326 
less than 20 min (Figure 5). Similarly, a burst drug release for 5-ASA matrix pellets in pH 6.8 327 
was reported which could be due to the action of the time-dependent swelling of Eudragit® 328 
polymers in the matrix of pellets [4]. Hence expected controlled drug release from matrix 329 
pellets could not be achieved.  330 
Since the performance of formulations depends on the transit time of the system in GIT, so 331 
they should be formulated by applying coats which are capable of delaying the drug release 332 
[43]. So, exerting ES100 as a coating layer could be an excellent candidate to control drug 333 
release. Therefore morphology, mechanical features and release behaviour of formulations 334 
were further analyzed using response surface methodology for selection of optimized 335 
formulation to be coated with ES100.  336 
Both aspect ratio (Figure 6A) and sphericity (Figure 6B) have negligible variation from the 337 
desired amount (sphericity 1 is an indication of a complete sphere), indicating that near 338 
spherical pellets were obtained. Overall the results showed that SA concentration and 339 
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polymer ratio did not affect the aspect ratio and sphericity of pellets. These results were in 340 
agreement with the findings of Abbaspour et al. which reported that the binder concentration 341 
and type of Eudragit® did not affect the shape and sphericity of pellets [17]. Thus, among the 342 
different response variables CS, MDTa, and MDTb were selected as the most representative to 343 
optimize the formulations. Mathematical relationships between the dependent and 344 
independent variables generated using Design-Expert® software, and the following equations 345 
were generated for the observed responses: 346 
Y3 = + 3.67 + 2.63 X1 + 2.79 X2 + 2.04 X1 X2 + 2.28 X12 - 2.29 X22  (7) 
Y4 = + 32.17 + 0.1194 X1 + 0.5984 X2 - 1.15 X1 X2 – 3.62 X12 – 13.88 X22  (8) 
Y5 = + 7.51 -13.55 X1 + 6.78 X2 - 11.60 X1 X2  (9) 
Analysis of variance indicated that the assumed regression models were significant and 347 
valid for each considered response shown in Table 4. 348 
Both the amount of SA and polymer ratio have a significant effect on the CS of pellets 349 
according to Eq. (7). Results indicate that by increasing the amount of SA, the hardness 350 
increases significantly (p-value, 0.0126). On the other hand, pellets containing a low amount 351 
of SA showed brittle behaviour under mechanical tests. However, the pellets containing 20% 352 
SA underwent a plastic deformation without any fracture (Figure 6C).  353 
This was probably due to the cross-linking of calcium ions with the SA, which makes 354 
matrices harder [44]. A high amount of SA resulted in a sticky formulation which produces 355 
hard pellets after thermal heating. Also in the presence of high amount of ERS, the elastic 356 
modulus and mechanical strength of pellets increased due to the melting of the ERS during 357 
the thermal heating. Similar results have also been proven in previous studies [45,46]. 358 
Eqs. (8) and (9) represent the quantitative effect of the amount of SA and polymer ratio on 359 
MDTa and MDTb of pellets. According to Figure 6D, an increase in MDTa was observed for 360 
the pellets containing 20% SA. That means these formulations have a slow drug release at pH 361 
1.2. Approximately an equal ratio of SA to calcium showed optimal release resistant. It was 362 
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probably due to the role of calcium in controlling the matrice swelling which is shown in 363 
many studies [47–49]. It should be noted that the higher amount of SA (40%) than calcium 364 
maybe resulted in extreme swelling of matrices which led to a decrease of MDTa. On the 365 
other hand, in matrices with a lower percentage of SA, swelling is not adequate to control the 366 
drug release.  367 
As seen in Figure 6E in the absence of SA, increasing the amount of ERS in pellets leads to 368 
rising MDTb. However, the presence of SA in the formulations decreases MDTb significantly 369 
(p-value, 0.0278) which is suitable from the point of drug release in the colon region.  370 
Once again the role of calcium in controlling the matrices swelling was highlighted. High 371 
water uptake of SA at pH 6.8 cause more swelling. Matrices with an equal ratio of SA to 372 
calcium showed better swelling than matrices without SA or higher amount of SA in the 373 
absence of calcium. According to the Figure 6E the presence of ES100 in matrix decreased 374 
MDTb but due to its negligible resistance to release in acidic medium is not desirable to use in 375 
the matrix. 376 
In order to check the validity of the generated equations in the optimization procedure, F2, F5 377 
and F8 formulations (with different SA concentrations) were selected to a comparative 378 
analysis of the observed and predicted values. No significant (p<0.01) difference between 379 
these two values (Table 5) indicated the validity of the generated model. Eventually, these 380 
formulations coat with ES100.  381 
Coated formulations which after this called F10, F11 and F12, showed resistance in the acidic 382 
medium. Drug release after 2h at pH 1.2 was 39.8, 29.5 and 39.8% for F10, F11, and F12 383 
formulations, respectively (Figure 7A). Results are compatible with findings of other studies 384 
that used the natural polymer as a core and subsequently coated with ES100 for colon 385 
targeting [50–52]. ES100 coating decreased the burst release of the drug to a great extent due 386 
to the coverage of pores and increased diffusion path length [41]. The increase in pH of the 387 
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dissolution media to 6.8 increased the drug release which could be due to the action of time-388 
dependent swelling of ERS in the matrix of pellets [4]. Also, at this pH the carboxylic groups 389 
of SA became ionized (COO-), resulting in swelling of the matrix [53]. Coated pellets 390 
containing SA (F11 and F12) released over 80% of their active ingredient after 6h (Figure 391 
7B). The percent of drug release was significantly higher at the pH 7.4 compared to pH 6.8 392 
(Figure 7C). It is because ES100 dissolves at pH 7.0 and forms a porous surface at the 393 
coating layer. This increased porous surface allowed entry of a large amount of dissolution 394 
media into the pellets leading to complete release of the drug [54]. Also, the increase in SA 395 
level to 40% had an effect on the drug release profiles. The release of 5-ASA from F12 396 
completed after 6h, while 90% of the drug was released after 10h in case of F10 and F11 397 
formulations.   398 
Formulation F11 was selected as the optimized formulation for studying continuous 399 
dissolution which provides a realistic in vitro simulation of the GIT. The pH gradient of the 400 
GIT is a most crucial physiological factor considered in the design of controlled release 401 
formulations. The coatings of these formulations were designed to resist the acidic medium of 402 
the stomach and dissolve in a more basic medium of the terminal ileum (around pH 7). 403 
However, consistent release of 5-ASA from these formulations may be hindered by 404 
fluctuations of intestinal pH levels in patients with UC, in whom colonic pH levels have been 405 
measured at lower than pH 7. Also, considerable tablet-to-tablet variability in dissolution has 406 
been observed for pH-dependent release formulation such as ASACOL® at pH<7. Therefore, 407 
in patients, the release of 5-ASA may be inconsistent and unpredictable from some oral 408 
formulations [55,56]. Results from the continuous dissolution test indicated that the designed 409 
colonic formulation (F11) could overcome these challenges. F11 released the 55.31 and 410 
89.23% of the drug at pH 6.8 and 7.4, respectively (Figure 8) so it can be used to treat a 411 
broader range of IBD patients with fluctuations of intestinal pH levels. 412 
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 413 
3.5. In vivo studies 414 
In vivo study was carried out in 5 groups. After two days of colitis induction, clinical 415 
symptoms such as prostration, diarrhoea, hypomotility, and weight-loss were observed in all 416 
animals (except normal control rats). The weight-loss was monitored daily after intracolonic 417 
administration of acetic acid (Figure 9). The treatment was carried out from day 5 to day 10. 418 
According to our results, colitis induction caused a significant weight loss compared to 419 
normal rats in all groups. The weight loss was continued from day 1 to 10 in negative control 420 
and vehicle-treated groups. The weight loss in negative control and vehicle-treated groups 421 
from day 1 to 10 was about 16% and 12%, respectively. The rate of weight loss in positive 422 
control and 5-ASA ES100 coated groups decreased from day 5 to day 7. From day 7 to day 423 
10, a small increase in weight (2-3%) was observed in the aforementioned groups which 424 
shows the efficacy of treatment strategy in the prevention of weight loss. On the final day, 425 
compared to the day 1, the percentage of the weight loss in the negative control group, 426 
vehicle-treated group, the positive control group, and 5-ASA ES100 coated group was 16%, 427 
12%, 5%, 8%, respectively. 428 
Histological evaluation was carried out on the final day of treatment. Representative 429 
photographs of colonic tissue indicated the anti-inflammatory benefit of 5-ASA ES100 430 
coated pellets and positive control groups compared to other groups (Figure 10). Images of 431 
macroscopic evaluations (Figure 10, upper panel) showed a normal colon with no 432 
macroscopic damage in the normal control group. The colon tissues in negative control and 433 
vehicle-treated groups were severely damaged, and mucosal congestion, haemorrhage, ulcers, 434 
and necrosis were observed and tangible. Administration of 5-ASA and 5-ASA ES100 coated 435 
pellets significantly alleviated the damaged tissues in the positive control group and 5-ASA 436 
coated pellets group. Compared to negative control group, photographs of H&E staining 437 
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(Figure 10, below panel) of colons revealed a decrease in the extensive necrotic destruction 438 
of epithelium, oedema, and ulceration at mucosal and sub-mucosal layers in positive control 439 
and 5-ASA ES100 coated pellets groups.  440 
A significant difference (p-value<0.001) between positive control (treated with 5-ASA 441 
pellets) and negative control groups was observed in reducing the inflammation severity in 442 
colon segment (Figure 11). The average of microscopic scores in negative control and 443 
vehicle-treated groups were 2.8±0.37 and 2.5±0.28, respectively, whereas the scores in 444 
positive control and 5-ASA ES100 coated pellets group was 0.8±0.48 and 1.8±0.23, 445 
respectively. The treatment with ES100 coated 5-ASA pellets could decrease the 446 
inflammatory score in the histopathological evaluation, and also it was statistically 447 
significant compared to the negative control group (p-value<0.05). No significant difference 448 
between 5-ASA pellets coated with ES100 and the positive control was observed (p-449 
value>0.05). This data indicated that the drug release from ES100 coated pellets into colon 450 
was almost similar to that from 5-ASA pellets. 451 
 452 
4. Conclusion 453 
Design of experiments was successfully used to investigate the effect of process variables on 454 
the characterization of pellets. Results showed that crushing strength and mean dissolution 455 
time of pellets were strongly dependent on sodium alginate concentration and polymer ratio. 456 
Sodium alginate concentration was an essential factor in designing formulations. In vitro 457 
data showed that uncoated formulations failed to control the 5-ASA release and burst release 458 
was observed. Meanwhile, the incorporation of Eudragit® S100 as pH-dependent coating 459 
layer improved the controlled release of pellets. Based on the release data of pellets, F11 460 
(20% sodium alginate and 30% Eudragit® RS coated with 10% Eudragit® S100) appears to 461 
be the best performing formulation. In vivo experiments revealed the therapeutic efficacy of 462 
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Eudragit® S100 coated pellets of 5-ASA in alleviating the conditions of induced colitis 463 
model as reflected by weight gain, as well as histological improvement. All these results 464 
confirmed the ability of this formulation for targeted drug delivery of 5-ASA to the colon. 465 
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 Table 1. The solid components of pellet formulations (based on percentage) 858 
Formulation 5-ASA Avicel Calcium Sodium 
alginate Eudragit
® RS  Eudragit® S100 
F1 20 20 10 0 40 10 
F2 20 20 10 0 25 25 
F3 20 20 10 0 10 40 
F4 20 20 10 20 24 6 
F5 20 20 10 20 15 15 
F6 20 20 10 20 6 24 
F7 20 20 10 40 8 2 
F8 20 20 10 40 5 5 
F9 20 20 10 40 2 8 
F10* 20 20 10 0 50 0 
F11* 20 20 10 20 30 0 
F12* 20 20 10 40 10 0 
       
 859 
  860 
 861 
 862 
 863 
            5-ASA                            Alginate                                                 864 
Eudragit 865 
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* Eudragit® S100 in the matrix was substituted as a coating layer. 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
Table 2. Experimental design 885 
Factors employed Level used 
 -1 0 1 
X1 = SA concentration (%) 0 20 40 
X2 = Ratio of ERS: ES100 4:1 1:1 1:4 
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 894 
 895 
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 897 
 898 
 899 
 900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
Table 3. The results of pellets characteristics 908 
Formulation  The yield of pellets (%)  Image analysis 
  Aspect ratio Sphericity 
F1  89  1.22 ± 0.13 0.81 ± 0.08 
F2  61  1.70 ± 0.53 0.67 ± 0.12 
F3  91  1.66 ± 0.25 0.61 ± 0.09 
F4  94  1.29 ± 0.16 0.78 ± 0.09 
F5  94  1.23 ± 0.21 0.83 ± 0.10 
F6  92  1.54 ± 0.24 0.66 ± 0.11 
F7  81  1.42 ± 0.24 0.72 ± 0.12 
F8  95  1.70 ± 0.30 0.49 ± 0.06 
F9  94  1.56 ± 0.24 0.65 ± 0.09 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
Table 4. Analysis of variance (ANOVA) of dependent variables 917 
Source of variation  Sum of squares  df  Mean square  F value  p-value 
Y3            
 Model  105.41  5  21.08  24.10  0.0126 
 Residuals  2.62  3  0.8747     
 Total  108.03  8       
 R2 =   0.9757         
Y4            
 Model  180.36  5  36.07  11.66  0.0351 
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 Residuals  9.28  3  3.09     
 Total  189.64  8       
 R2 =   0.9511         
Y5            
 Model  1667.92  3  555.97  7.37  0.0278 
 Residuals  377.40  5  75.48     
 Total  2045.32  8       
 R2 =   0.9374         
 918 
 919 
 920 
 921 
 922 
 923 
 924 
 925 
 926 
 927 
 928 
 929 
 930 
 931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
 947 
 948 
 949 
Table 5. Predicted and experimental value of responses for selected formulations 950 
 F2  F5  F8 
 Observed Predicted Residual  Observed Predicted Residual  Observed Predicted Residual 
Y3 4.86 4.17 0.69  4.31 5.19 -0.88  9.22 6.40 2.82 
Y4 10.49 18.88 -8.39  18.24 18.53 -0.29  14.47 17.89 3.42 
Y5 25.66 15.29 10.37  9.98 10.26 -0.28  6.29 5.23 1.06 
 951 
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Table 6. Criteria for macroscopic and histological scoring of damage 952 
Scores Macroscopic criteria Histological criteria* 
0 No or mild inflammation Gablet cell depletion 
1 Acute focal inflammation Crypt abscess formation 
2 Acute spread inflammation Muscle thickening 
3 Ulceration with inflammation Cellular infiltration 
4 Gangrene and necrosis Loss of mucosal architecture 
* Each of these criteria may be present or absent in these scores 953 
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Figure 1. In vivo rat study design: Colitis was induced on day 0 (except for normal control groups). 971 
Oral administration of the different formulations began on day 5. All animals received standard chow 972 
(standard laboratory feeding pellets). 973 
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Figure 2. SEM of uncoated (A) and coated pellet at 250× (B) and 2500× (C), the thickness of the 975 
coating (D) at 3000×, coated pellet after continuous dissolution test at 250× (E) and 2500× (F) 976 
magnifications.  977 
 978 
 979 
Figure 3. FTIR Spectra of drug, polymers, and physical mixture of drug and polymers. (a) 5-ASA, (b) 980 
ES100, (c) ERS, (d) alginate, (e) pellet and (f) physical mixture of ES100, ERS and alginate 981 
polymers. 982 
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 983 
Figure 4. DSC curves of (a) 5-ASA, (b) ES100, (c) ERS, (d) alginate, (e) pellet and (f) physical 984 
mixture of ES100, ERS and alginate polymers. 985 
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Figure 5. The dissolution profile of uncoated formulations in the media with pH 1.2 (A) and 6.8 (B). 987 
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(D) (E) 
 
 
Figure 6. Response surface plot is showing the influence of sodium alginate concentration and 1001 
polymer ratio on the aspect ratio (A), sphericity (B), crushing strength (C) and mean dissolution time 1002 
in pH 1.2 (D) and 6.8 (E). 1003 
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Figure 7. The dissolution profile of coated formulations in the media with pH 1.2 (A), 6.8 (B) and 7.4 1012 
(C)  1013 
 1014 
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Figure 8. The continuous dissolution profile of coated F11. 1015 
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 1016 
 1017 
Figure 9. Determination of weight loss (mean± SEM) during the whole experimental period for n=5 1018 
animals in each group. ***p-value<0.001 compared to control negative group. 1019 
 1020 
Figure 10. Representative macroscopic and histological appearance of rat colonic mucosa. The colon 1021 
samples of normal (non-colitis) and negative control groups, rats receiving vehicle (1% Na CMC), 5-1022 
ASA (positive control group) and 5-ASA ES100 coated pellets were collected for histological analysis 1023 
in the final day of treatment. Macroscopic photographs (upper panel) and microscopic appearances 1024 
after H&E staining (below panel) of the colon samples were shown. Magnification was equivalent for 1025 
all macroscopic images and 20× for H&E staining images. 1026 
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 1028 
Figure 11. Histopathological inflammation scores determination (mean±SEM) for n=5 animals in 1029 
each group on the final day (day10). ***p-value<0.001,*p-value<0.05 compared to negative control 1030 
group. 1031 
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Figure 1. In vivo rat study design: Colitis was induced on day 0 (except for normal control groups). Oral administration of the different formulations began on 
day 5. All animals received standard chow (standard laboratory feeding pellets). 
 
